# Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer

> **NCT00107315** · PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 16 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00107315
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Terminated due to low accrual
- **Last updated:** 2014-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107315, "Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00107315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*